Close Menu

NEW YORK – A new experimental blood test could provide clinicians with information on pancreatic cancer patients who won't respond to traditional treatments such as chemotherapy.

The test, developed by researchers at Van Andel Institute in Grand Rapids, Michigan, measures the levels of a certain glycan, sTRA, to determine which cancer subtype patients have and whether it will react to chemotherapy and/or surgery.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.